KMMH Portable Magnetic Resonance Imaging System (2026)

Location

Description

Kent and Medway Mental Health NHS Trust (the “Trust”) hereby gives notice of its intention to directly award a contract for the provision of a portable low-field (0.064 Tesla) magnetic resonance imaging (MRI) system. The contract will also include the provision of associated peripherals, together with training, support and maintenance services, for a period of five (5) years. The MRI system will be utilised to support the acceleration and development of local, place-based neuroimaging research, particularly in relation to the assessment and diagnosis of dementia, where timely access to imaging is frequently a rate-limiting factor. The system will also be made available to support research into other mental health conditions, including initiatives aligned to the Kent Complex Psychosis Service and wider investigation into non-dementia mental illness affecting both older and younger adults. A key objective of this programme is to facilitate the development of new artificial intelligence (AI) algorithms for the assessment of structural brain changes associated with dementia and cognitive decline. This is intended to reduce reliance on high-field MRI imaging within specialist centres and to avoid the associated restrictive clinical environments. In order to support these research objectives, the Trust requires a system that meets the following essential criteria: • Approval for commercial sale in the United Kingdom (UKCA marking); • A compact and highly portable design, capable of passing through standard doorways and elevators and allowing ease of manoeuvrability within clinical environments; • A magnetic configuration that enables researchers to work safely in close proximity to participants during imaging procedures; • Operation via standard electrical power outlets; • Low power consumption to minimise ongoing operational costs; • An open design to reduce participant anxiety and improve patient experience; and • Operation via a portable, user-friendly wireless device (for example, a tablet). The Trust considers that the direct award of this contract is justified pursuant to paragraph 6 of Schedule 5 to the Procurement Act 2023. Accordingly, the Trust is publishing this Transparency Notice to inform the market of its intention to enter into the contract by way of direct award. Following publication of this Transparency Notice, the Trust intends to publish a Contract Award Notice to confirm the outcome of the procurement process and to notify the market of its intention to enter into the contract. The publication of the Contract Award Notice will initiate a mandatory standstill period of eight (8) working days. The Trust will not enter into the contract prior to the publication of the Contract Award Notice and the expiry of the applicable standstill period. The dates and contract values included in this Transparency notice are provided for indicative purposes only. The final details will be confirmed in the subsequent publication of the Contract Award Notice. The Trust expressly reserves the right not to award any contract as a result of this notice.

Award Detail

CPV Codes

• None found

Legal Justification

The Trust considers that the direct award of this contract is justified pursuant to paragraph 6 of Schedule 5 to the Procurement Act 2023., whereby the following conditions are met: (a) due to an absence of competition for technical reasons, only a particular supplier can supply the goods, services or works required, and (b) there are no reasonable alternatives to those goods, services or works. Following the completion of appropriate market research, the Trust is satisfied that the required goods and associated services can only be supplied by a single economic operator, and that no reasonable alternatives or substitutes exist. This conclusion is informed by the Trust’s core requirements for a portable, low-field MRI system that is optimally suited to support the acceleration and development of local, place-based neuroimaging clinical research. The essential characteristics of the required system include: • Approval for commercial sale in the United Kingdom (UKCA marking); • A compact and highly portable design, capable of passing through standard doorways and elevators and allowing ease of manoeuvrability within clinical environments; • A magnetic configuration that enables researchers to work safely in close proximity to participants during imaging procedures; • Operation via standard electrical power outlets; • Low power consumption to minimise ongoing operational costs; • An open design to reduce participant anxiety and improve patient experience; and • Operation via a portable, user-friendly wireless device (for example, a tablet). The Trust considers that Xiel Ltd is the exclusive UK distributor of the Hyperfine Portable MR Imaging System and is therefore the only economic operator capable of supplying an existing solution that meets the above requirements. Accordingly, Xiel Ltd is deemed to be the sole supplier able to support the Trust’s objectives for delivering local, place-based neuroimaging clinical research within the required timescales.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **